Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Chemoradiation in Limited-Stage SCLC
NCT00387699Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2006
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bevacizumab in small cell lung cancer (SCLC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Progression-Free Survival at 1 year. Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00387699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387699.